GLP-1 brands such as Ozempic, Wegovy and Mounjaro have captured the public imagination for their weight-loss benefits, leading to rapid growth in new-to-brand prescribing over the past 12 months and brand shortages.
The impact of GLP-1s across multiple spaces including bariatric surgery, cardiovascular devices, diabetes, orthopedics, and sleep apnea, could have profound implications on the MedTech industry, with GLP-1 inhibitor sales to surpass $17bn by 2031.
IQVIA MedTech has the data and insights you need to weigh up the potential impact on your business and make smart decisions for the future.
Complete the form on this page to find out more about IQVIA MedTech and stay ahead of business-critical trends.
Please fill out the form to speak to an IQVIA MedTech expert.
